NCT05821374View on ClinicalTrials.gov

Deucravacitinib in PG

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 29, 2024

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

Deucravacitinib

6 mg tablet

Trial Locations (1)

03576

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT05821374 - Deucravacitinib in PG | Biotech Hunter | Biotech Hunter